Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexCryptocurrenciesCybersecurityPress Releases

Japanese shares fall on energy rout, economic slowdown fears

07/05/2022 | 11:04pm EDT

TOKYO, July 6 (Reuters) - Japanese shares fell on Wednesday, with energy stocks leading losses, as sentiment was weighed by fears of a global economic slowdown.

The Nikkei share average fell 1.26% to 26,089.86 by the midday break, while the broader Topix slipped 1.37% to 1,853.41. "Investors' focus have shifted to slowdown risks stemming from the ongoing tightening monetary policy," said Ikuo Mitsui, fund manager at Aizawa Securities.

"Wall Street rose overnight but that was because investors bought back growth shares that were beaten-down on concerns about rate increases."

In Japan, oil explorers tumbled almost 10% to become the worst performer among the 33 industry sub-indexes on the Tokyo Stock Exchange.

Crude futures rebounded on Wednesday as investors piled back in after the heavy rout in the previous session, shifting their focus again to supply concerns even as worries about a recession mounted.

Refiners lost 6.33% and utilities fell 4.71%.

Oil explorer Inpex was the worst performer on the Nikkei, down 9.92%, followed by refiner Idemitsu Kosan, which lost 7.89%. Utility Tokyo Electric Power Company Holdings tumbled 7.35%.

Travel and leisure-related shares also fell, as mass COVID-19 testing in China stocked fears of potential lockdowns.

Railways and airliners slipped 1.57% and 2.85%, respectively.

Trading firms Mitsui & Co and Mitsubishi Corp fell 5.71% and 5.4%, respectively, after former Russian president Dmitry Medvedev made comments threatening the loss of oil and gas supply to Japan.

Bucking the trend, Eisai jumped 4.89% after the drug maker and its partner Biogen said the U.S. Food and Drug Administration will expedite its review of experimental Alzheimer's drug lecanemab.

(Reporting by Junko Fujita; Editing by Amy Caren Daniel)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 39.85% 276.61 Delayed Quote.-17.56%
EISAI CO., LTD. 17.29% 6784 Delayed Quote.-11.44%
IDEMITSU KOSAN CO., LTD. -0.78% 3160 Delayed Quote.8.44%
INPEX CORPORATION -1.11% 1333 Delayed Quote.34.53%
LONDON BRENT OIL 3.53% 89.21 Delayed Quote.7.68%
MITSUBISHI CORPORATION -0.48% 4143 Delayed Quote.13.99%
MITSUI & CO., LTD. 0.74% 3151 Delayed Quote.14.85%
NIKKEI 225 -1.50% 26173.98 Real-time Quote.-7.71%
TOKYO ELECTRIC POWER COMPANY HOLDINGS, INC. -1.07% 462 Delayed Quote.57.24%
TOPIX INDEX -0.95% 1855.15 Delayed Quote.-5.99%
WTI 4.20% 81.872 Delayed Quote.4.16%
Latest news "Economy & Forex"
05:51pWorkiva gets takeover interest from Thoma Bravo, TPG - Bloomberg News
RE
05:50pPeru indigenous groups block river in the Amazon after oil spill
RE
05:48pIMF agrees $293 million financing for Barbados, first deal under new trust fund
RE
05:48pFlorida governor desantis says storm surge from hurricane ian ha…
RE
05:47pQuebec premier: Adding immigrants who do not speak French would be 'suicidal'
RE
05:46pFlorida governor desantis says hurricane ian will cause damage '…
RE
05:41pUtilities Up on Cyclical Bias -- Utilities Roundup
DJ
05:40pCommunications Services Up on Risk-Appetite Rebound -- Communications Services Roundup
DJ
05:39pThe WSJ Dollar Index Falls 1.00% to 104.09 -- Data Talk
DJ
05:39pEuro Gains 1.46% to $0.9736 -- Data Talk
DJ
Latest news "Economy & Forex"